The evolution of chemoradiation for glioblastoma: a modern success story.
The dismal prognosis of glioblastoma had remained unchanged for the past 30 years until the association of temozolomide and radiotherapy in the breakthrough European Organization for Cancer/National Cancer Institute of Canada (EORTC/NCIC) trial brought new hope for patients. This trial will serve as a platform for new and exciting clinical and translational research areas. We review here the role of standard radiotherapy and chemotherapy in glioblastoma and the potential causes of their failure, and we focus on some of the aspects that led to the successful EORTC/NCIC trial and some of the related studies.
Mirimanoff
René-Olivier
RO
Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) Rue du Bugnon 46, CH-1011 LAUSANNE, Switzerland. rene-olivier.mirimanoff@chuv.ch
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide